Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.
Stocks quotes in this article: ALKS, CYTR, DVAX, ITCI, NOVN, PTLA, PTCT, RIGL, TGTX

President Trump recently criticized the FDA approval process as "slow and burdensome" but failed to offer up specific plans for reform. If FDA standards were to be altered, the market could see an avalanche of new drugs and treatments. TheStreet's Adam Feuerstein compiled the "Gnarly Nine" companies that could be interesting to watch as the FDA enters the Trump era. 

  1. Alkermes (ALKS)

  2. CytRX (CYTR)

  3. Dynavax Technologies (DVAX)

  4. Intra-Cellular Therapies (ITCI)

  5. Novan (NOVN)

  6. Portola Pharmaceuticals (PTLA)

  7. PTC Therapeutics (PTCT)

  8. Rigel Pharmaceuticals (RIGL)

  9. TG Therapeutics (TGTX)

READ THE FULL STORY HERE: These 'Gnarly 9' Biotechs Will Test the FDA's Mettle
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

This article was written by a staff member of TheStreet.
TAGS: Investing | Video | Natural Gas | Healthcare | Consumer Services | Opinion | Commercial & Professional Services | Politics | Drug Approvals | Financial Services

More from Video

One Tweet Pulls the Rug Out From Under the Indexes

James "Rev Shark" DePorre

Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.

A Technical Look at the New Dow Jones Industrial Average

Bruce Kamich

Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.

Conagra Brands Looks Tastier After Its Upgrade to Buy

Bruce Kamich

CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.

Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts

Bruce Kamich

Breaking down an approach to the long side of this biotech stock.

Is Renewable Energy the Defensive Stock Opportunity You're Missing

Kevin Curran

AMSC CEO discusses that and China challenges.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight